Data to be presented at Molecular Med Tri-Con Virtual Conference SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects
Target Selector™ EGFR assays offer ultra-high sensitivity and require less tumor sample than most commercial assays SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean
COVID-19 test, based on Aegea’s next-generation COVID-19 assay kit using Switch-Blocker™ technology, may provide answers that support screening and managing patients SAN DIEGO --(BUSINESS WIRE)--Mar. 2, 2021-- Aegea Biotechnologies, Inc. , an innovative life science company with an extensive
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received SAN DIEGO
SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021
Q4 features revenues of $18.5 million ; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m.
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees.
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University W ebinar begins tomorrow, April 8 , at 12:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2021-- Biocept, Inc.
